ACCOLATE
Pronunciation: za-FIR-loo-kast

What it isCysteinyl-leukotriene receptor antagonist; maintenance treatment of asthma.
Why this oneUnlike montelukast, it has clinically important warfarin and food interactions and greater hepatotoxicity concern.
What limits itTake on an empty stomach and monitor liver symptoms; CYP2C9 inhibition can raise warfarin and requires closer INR monitoring.
Animated chart of estimated U.S. prescriptions per year, Asthma/COPD meds (1924–2026). Zafirlukast enters in 1996 (estimated).
Principal riskIt inhibits CYP2C9 and raises warfarin
Legacy pregnancy categoryC
Defining liabilityHepatotoxicity, occasionally fatal or requiring transplant; raises warfarin effect (prothrombin time). Watch for liver symptoms and anticoagulation.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Asthma (prophylaxis and chronic treatment) | adults & children ≥12 yr | 20 mg BID | 20 mg BID | 20 mg BID |
| Asthma | children 5-11 yr | 10 mg BID | 10 mg BID | 10 mg BID |
Renal No adjustment needed
Hepatic Contraindicated (hepatic impairment including cirrhosis)
Available strengths
Pregnancy Undefined
Lactation Undefined
Generic entry2010
Open Zafirlukast in the interactive console ↗